Reye syndrome and sudden death symptoms after oral administration of nimesulide due to upper respiratory tract infection in a boy
FENG Li-Fang1, CHEN Xiao-Hong1, LI Dong-Xiao2, LI Xi-Yuan2, SONG Jin-Qing2, JIN Ying2, YANG Yan-Ling2
Department of Endocrinology and Metabolism, Tongji Medical College, Wuhan Children's Hospital, Huazhong University of Science and Technology, Wuhan 430015, China
Abstract A boy aged 6 years and 3 months developed upper respiratory tract infection and pyrexia 2 months ago and was given oral administration of nimesulide by his parents according to directions. Half an hour later, the boy experienced convulsions and cardiopulmonary arrest, and emergency examination found hypoketotic hypoglycemia, metabolic acidosis, significant increases in serum aminotransferases and creatine kinase, and renal damage. Recovery of consciousness and vital signs was achieved after cardiopulmonary resuscitation, but severe mental and movement regression was observed. The boy had a significant reduction in free carnitine in blood and significant increases in medium-and long-chain fatty acyl carnitine, urinary glutaric acid, 3-hydroxy glutaric acid, isovalerylglycine, and ethylmalonic acid, suggesting the possibility of multiple acyl-CoA dehydrogenase deficiency. After the treatment with vitamin B2, L-carnitine, and bezafibrate, the boy gradually improved, and reexamination after 3 months showed normal biochemical parameters. The boy had compound heterozygous mutations in the ETFDH gene, i.e., a known mutation, c.341G > A (p.R114H), from his mother and a novel mutation, c.1484C > G (p.P495R), from his father. Finally, he was diagnosed with multiple acyl-CoA dehydrogenase deficiency. Reye syndrome and sudden death symptoms were caused by nimesulide-induced acute metabolic crisis. It is concluded that inherited metabolic diseases may be main causes of Reye syndrome and sudden death, and biochemical and genetic analyses are the key to identifying underlying diseases.
FENG Li-Fang,CHEN Xiao-Hong,LI Dong-Xiao et al. Reye syndrome and sudden death symptoms after oral administration of nimesulide due to upper respiratory tract infection in a boy[J]. CJCP, 2018, 20(11): 944-949.
FENG Li-Fang,CHEN Xiao-Hong,LI Dong-Xiao et al. Reye syndrome and sudden death symptoms after oral administration of nimesulide due to upper respiratory tract infection in a boy[J]. CJCP, 2018, 20(11): 944-949.
Reye RD, Morgan G, Baral J. Encephalopathy and fatty degeneration of the viscera. A disease entity in childhood[J]. Lancet, 1963, 2(7311):749-752.
[2]
Newton L, Hall SM. Reye's syndrome in the British Isles:report for 1990/91 and the first decade of surveillance[J]. Commun Dis Rep CDR Rev, 1993, 3(1):R11-R16.
[3]
Hardie RM, Newton LH, Bruce JC, et al. The changing clinical pattern of Reye's syndrome 1982-1990[J]. Arch Dis Child, 1996, 74(5):400-405.
[4]
Donati M, Conforti A, Lenti MC, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs:data from drug-induced liver injury case-control study in Italy[J]. Br J Clin Pharmacol, 2016, 82(1):238-248.
[5]
Yotsumoto Y, Hasegawa Y, Fukuda S, et al. Clinical and molecular investigations of Japanese cases of glutaric acidemia type 2[J]. Mol Genet Metab, 2008, 94(1):61-67.
[6]
Grunert SC. Clinical and genetical heterogeneity of lateonset multiple acyl-coenzyme A dehydrogenase deficiency[J]. Orphanet J Rare Dis, 2014, 9:117.
[7]
Belay ED, Bresee JS, Holman RC, et al. Reye's syndrome in the United States from 1981 through 1997[J]. N Engl J Med, 1999, 340(18):1377-1382.
[8]
Yoshida I, Yamashita F. The changing age distribution of Reye's syndrome in the United States and a critique of the CDC criteria[J]. Acta Paediatr Jpn,1990, 32(4):378-380.
[9]
Orlowski JP. Whatever happened to Reye's syndrome? Did it ever really exist?[J]. Crit Care Med, 1999, 27(8):1582-1587.
[10]
Green A, Hall SM. Investigation of metabolic disorders resembling Reye's syndrome[J]. Arch Dis Child, 1992, 67(10):1313-1317.
[11]
Hernández N, Bessone F, Sánchez A, et al. Profile of idiosyncratic drug induced liver injury in Latin America:an analysis of published reports[J]. Ann Hepatol, 2014, 13(2):231-239.
[12]
Kshirsagar NA, Bachhav SS. Nimesulide controversy:a comparison of EU and Indian scenario[J]. Int J Risk Saf Med, 2013, 25(4):239-246.
Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity[J]. Curr Med Chem, 2009, 16(23):3041-3053.
[17]
Przyrembel H, Wendel U, Becker K, et al. Glutaric aciduria type Ⅱ:report on a previously undescribed metabolic disorder[J]. Clin Chim Acta,1976, 66(2):227-239.
Singh BK, Tripathi M, Pandey PK, et al. Nimesulide aggravates redox imbalance and calcium dependent mitochondrial permeability transition leading to dysfunction in vitro[J]. Toxicology, 2010, 275(1-3):1-9.
[20]
Licata A, Calvaruso V, Cappello M, et al. Clinical course and outcomes of drug-induced liver injury:nimesulide as the first implicated medication[J]. Dig Liver Dis, 2010, 42(2):143-148.
[21]
Mingatto FE, dos Santos AC, Rodrigues T, et al. Effects of nimesulide and its reduced metabolite on mitochondria[J]. Br J Pharmacol, 2000, 131(6):1154-1160.
[22]
Ong MM, Wang AS, Leow KY, et al. Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2(+/-) mice[J]. Free Radic Biol Med, 2006, 40(3):420-429.
Ersoy EO, Rama D, Ünal Ö, et al. Glutaric aciduria type 2 presenting with acute respiratory failure in an adult[J]. Respir Med Case Rep, 2015, 15:92-94.
Csiky B, Bene J, Wittmann I, et al. Effect of hemodialysis session on the dynamics of carnitine ester profile changes in L-carnitine pretreated end-stage renal disease patients[J]. Int Urol Nephrol, 2013, 45(3):847-855.
[34]
Yahyaoui R, Rueda I, Dayaldasani A, et al. C5-carnitine false positive results in newborn screening:what is the cause?[J]. Med Clin (Barc), 2015, 144(4):181-182.
[35]
Yamada K, Kobayashi H, Bo R, et al. Elevation of pivaloylcarnitine by sivelestat sodium in two children[J]. Mol Genet Metab, 2015, 116(3):192-194.
[36]
Yamaguchi S, Li H, Purevsuren J, et al. Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders:evaluation by in vitro probe acylcarnitine assay[J]. Mol Genet Metab, 2012, 107(1-2):87-91.
[37]
Zhu M, Zhu X, Qi X, et al. Riboflavin-responsive multiple AcylCoA dehydrogenation deficiency in 13 cases, and a literature review in mainland Chinese patients[J]. J Hum Genet, 2014, 59(5):256-261.
[38]
Henriques BJ, Rodrigues JV, Olsen RK, et al. Role of flavinylation in a mild variant of multiple acyl-CoA dehydrogenation deficiency:a molecular rationale for the effects of riboflavin supplementation[J]. J Biol Chem, 2009, 284(7):4222-4229.
